Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer’s disease model
© The Author(s). 2017
Received: 15 October 2016
Accepted: 7 April 2017
Published: 24 April 2017
Microglia mediate amyloid-beta peptide (Aβ)-induced neuroinflammation, which is one of the key events in the pathogenesis of Alzheimer’s disease (AD). Decoy receptor 3 (DcR3)/TNFRSF6B is a pleiotropic immunomodulator that promotes macrophage differentiation toward the M2 anti-inflammatory phenotype. Based on its role as an immunosupressor, we examined whether DcR3 could alleviate neuroinflammation and AD-like deficits in the central nervous system.
We crossed human APP transgenic mice (line J20) with human DcR3 transgenic mice to generate wild-type, APP, DcR3, and APP/DcR3 mice for pathological analysis. The Morris water maze, fear conditioning test, open-field, and elevated-plus maze were used to access their cognitive behavioral changes. Furthermore, the pathological and immune profiles were examined by immunostaining, ELISA, Q-PCR, and IP. In vitro assays were designed to examine DcR3-mediated innate cytokine profile alteration and the potential protective mechanism.
We reported that DcR3 ameliorates hippocampus-dependent memory deficits and reduces amyloid plaque deposition in APP transgenic mouse. The protective mechanism of DcR3 mediates through interacting with heparan sulfate proteoglycans and activating IL-4+YM1+ M2a-like microglia that reduces Aβ-induced proinflammatory cytokines and promotes phagocytosis ability of microglia.
The neuroprotective effect of DcR3 is mediated via modulating microglia activation into anti-inflammatory M2a phenotype, and upregulating DcR3 expression in the brain may be a potential therapeutic approach for AD.
KeywordsAlzheimer's Disease Neuroinflammation Decoy Receptor 3 M2a microglia
Alzheimer’s disease (AD) is the most common incurable neurodegenerative disease. One of the pathological hallmarks of AD is the extracellular amyloid plaques composed of amyloid-beta peptide (Aβ) which is generated by proteolytic cleavage of amyloid precursor protein (APP). The abnormal accumulation of Aβ is considered to be a critical factor in AD pathogenesis [1, 2]. The aggregation of Aβ into small oligomers and fibrillar plaques triggers neuroinflammation that contributes to the neuronal loss and cognitive decline [1, 3]. Although suppression of chronic inflammation has been proposed as a new direction for AD intervention, the therapeutic effects of anti-inflammatory drugs in current clinical trials are far from satisfactory . Therefore, a novel strategy is necessary to protect neurons from Aβ-induced neurotoxicity and neuroinflammation to preserve memory.
Microglia serve as the first line of host defense in the brain. Microglia activation can be beneficial or detrimental in AD pathogenesis via removing Aβ by phagocytosis or producing pro-inflammatory cytokines that damage neurons [5, 6]. The activated microglia are classified into M1 inflammatory (classical) and M2 anti-inflammatory (alternative) phenotypes . The M1 phenotype can be triggered by lipopolysaccharides, interferon-γ, and Aβ. They produce pro-inflammatory cytokines, such as IL-1β and TNF-α [8, 9], to kill pathogens and induce cytotoxicity . In contrast, the M2 microglia reduce Aβ plaque deposition and alleviate memory impairments in an AD mouse model . Therefore, modulation of microglia activation and differentiation is a potential approach to regulate neuroinflammation in AD [11, 12]. M2 phenotype microglia can be divided into M2a-d subtypes according to the surface and intracellular markers [13, 14]. The M2a subtype microglia (YM1+, FIZZ1+, CCL17+, arginase-1+) are induced by IL-4, IL-13, fungal and helminth infections and are capable of suppressing inflammation . However, the functions of these microglia subtypes are still controversial assayed in different in vitro systems [16–18].
Decoy receptor 3 (DcR3)/TNFRSF6B is a soluble decoy receptor which can neutralize the biological functions of three members of tumor necrosis factor superfamily: Fas ligand (FasL) LIGHT, and TL1A to reduce cell death [19–21]. In addition to its neutralizing effect, DcR3 interacts with heparan sulfate proteoglycans (HSPGs) to promote the differentiation of M2-like macrophages through epigenetic regulation [22–24]. DcR3 upregulates the expression of M2 macrophage markers (mannose receptor/CD206, arginase-I, YM-1, CD86, MMP7 and MMP-9) and downregulates the expression of M1 markers (iNOS, CD80, FcγR, IL-6, and TNF-α) [24, 25]. DcR3 transgenic mice are resistant to type-I diabetes and Th17-mediated autoimmune diseases . However, the role of DcR3 in Aβ-mediated neuroinflammation in the brain has not yet been identified.
Given that DcR3 exerts anti-apoptotic and immune-modulatory effects via neutralizing FasL and non-deoy functions we asked whether DcR3 ameliorates AD-like functional deficits and pathological changes using both in vivo and in vitro systems. Here, we demonstrated that Aβ-induced cognitive deficits and neurodegeneration were improved by DcR3 in transgenic mice overexpressing a mutated human APP minigene (hAPP/J20 line). DcR3 skewed microglia differentiation to IL-4+YM1+ M2a-like subtype, modulated neuroinflammation, conserved synaptic density, and reduced Aβ. Our observations suggest that DcR3 may become a promising reagent for the treatment of AD in the future.
Hemizygous hAPP transgenic mice (line J20) express an alternatively spliced human APP minigene with the Swedish and Indiana familial AD mutations driven by the PDGF promoter . Hemizygous DcR3 transgenic mice express human DcR3 driven from the CD68 promoter in macrophages/microglia/monocytes . Female DcR3 transgene mice were crossed with male APP transgenic mice to obtain wild-type DcR3 single transgenic, APP single transgenic, and APP/DcR3 double transgenic mice. The littermates of these mice were examined in behavioral tests at 6 months of age and sacrificed for pathological examinations at 6 or 12 months of age.
Morris Water Maze
The water maze consisted of a water pool (122 cm in diameter) containing opaque water and a platform (10 cm in diameter) submerged 1 cm below the water surface. The hidden platform test consisted of 10 sessions over 5 days and each session comprised three 60-s trials with 15-min inter-trial intervals. The platform location remained constant during the hidden platform sessions, and the entry points were changed semi-randomly between days. One day after the final day of hidden platform training section, a probe trial was conducted by removing the platform and allowing mice to explore in the pool for 1 min. The quadrant in which the platform was previously located was defined as the target quadrant, and the proportion of time (as a percentage) that the each mouse spent in the target quadrant was used to measure memory retention. The number of platform crossings and swim speed were recorded and analyzed with the EthoVision video tracking system (Version 3.1 Noldus Wageningen, Netherlands).
During the day 1 training section mice were habituated in a conditioning box (Graphic State 2.101 Contents, Coulbourn Instruments, PA, USA) for 5 min and then received five pairs of an 8-s tone and a 2-s shock (0.4 mA) followed by a 2-min resting interval. On day 2 testing sections, the trained mice were placed back to the same testing box, and their freezing time was scored for 5 min to measure the contextual conditioned fear response. The cued test was conducted 5 min after the contextual test. Mice were habituated for 5 min in a novel-shaped box and then exposed to three 10-s auditory cues followed with a 2-min resting interval. The freezing times of each mouse were scored during all testing sessions.
To detect spontaneous locomotor activity mice were placed in an open chamber (24.32 × 24.32 cm2). Their horizontal movement was detected by a 16 × 16 infrared photo-beam arrays placed 1.5 cm above the bottom of the chamber for 15 min (Version 2.0, TRU Scan Photobeam LINC, Coulbourn Instruments, PA, USA).
Elevated plus maze
The elevated plus-shaped maze consisted of two open arms and two closed arms. All mice were individually placed at the center of the maze and allowed to explore for 10 min. The time spent and distances traveled on each arm were calculated with the Etho Vision video tracking system.
Immunofluorescence and thioflavin-S staining
Paraformaldehyde-fixed brains were sliced coronally by using a microtome (Leica SM2010R Heidelberg, Germany) and were stored in cryoprotectant medium (30% glycerol, 30% ethylene glycol in PBS) at -20 °C. For immunohistochemistry (IHC) staining, brain slices were blocked in a TBS-buffered solution containing 1% glycine, 0.4% Triton X-100, 10% FBS (FBL01, Caisson labs, USA), 0.1% sodium azide (13412, Sigma, MO, USA) and 3% serum bovine albumin for 2 h and then incubated for 24 h at 4 °C with anti-Iba1 (019–19741, Wako), anti-YM1 (01404, Stem Cell technology), anti-synaptophysin (04–1019, Millipore), anti-MAP2 (MAB378, Millipore) and anti-Aβ (SIG-39320, 6E10, Covance) to measure the distribution of microglia, M2a activated microglia, pre-synaptic density, neuronal density and the total level of Aβ. After incubation, the slices were incubated for 2 h with Alexa594-labeled (111–585–003, Jackson ImmunoResearch) and Alexa488-labeled secondary antibodies (115–546–003, Jackson ImmunoResearch) at room temperature.
For thioflavin-S staining brain slices were incubated with 0.015% thioflavin-S (T1892; Sigma MO, USA) for 15 min at room temperature. All chemicals unless otherwise stated were purchased from Bio Basic Inc. (Canada).
For immunocytochemistry staining primary cells were fixed with 4% paraformaldehyde to measure the degeneration of primary neurons and the morphology changes of microglia in responses to different treatment conditions. Fixed cells were stained with anti-MAP2 or anti-Iba1 antibody to visualize the structure changes. The stained slices or cells were imaged with a fluorescence microscope (Axio Observer A1; Zeiss Germany) or a confocal microscope (Fluoview FV10i; Olympus USA). Images were analyzed with MetaMorph® Microscopy Automation & Image Analysis Software (Molecular Devices, CA, USA).
To quantify the total or M2a microglia surrounding plaques slices were double stained with 6E10 and anti-Iba1 or anti-YM1 antibodies. Plaque areas were circled to determine the centers. The circles were then enlarged 10 μm in radius from the center, which was considered to be the periphery area for measuring the microglia or secreted YM1 coverage.
Enzyme-linked immunosorbent assays (ELISAs)
For DcR3 measurement up to 500 μl of blood was collected from the facial vein at the submandibular area and was centrifuged at 1,000 g for 15 min to isolate the serum. Serum DcR3 concentrations were measured with a human DcR3 Duo Set (DY142, R&D, USA).
For Aβ measurement the hippocampus of each mouse was homogenized in 5 M guanidine/5 mM Tris (pH 8.0) buffer and diluted with 0.25% casein blocking buffer to a final concentration of 0.5 M guanidine with protease inhibitor (04693116001, Roche, Basel, Switzerland). The levels of total Aβ and Aβ42 were quantified using Aβ ELISA kits (27729 and 27711, IBL, Hamburg, Germany).
For cytokines measurement diluted hippocampus lysates and conditioned media were applied to TNF-α, IL-1β, and IL-6 ELISA kits (555268, 559603, 555240, BD System, NJ, USA). For YM1 measurement, the hippocampus was homogenized in diluting reagent provided by ELISA kit at the concentration of 20 μg tissue/μl, and YM1 concentration were measured using mouse YM1/Chitinase 3-like 3 DuoSet ELISA (DY2446, R&D, USA).
Quantitative real-time PCR (Q-PCR)
The RNA from the hippocampus and the primary microglia were purified using the Total RNA Mini Kit (Geneaid Taiwan) or TRI reagent (T9424, Sigma, MO, USA), and then immediately reverse transcribed into cDNA by MMLV high-performance reverse transcriptase (RT80125K, Epicentre, WI, USA). The mRNA expression levels were analyzed by using primers (listed in Additional file 1: Table S1) mixed with SYBR Green PCR Master Mix (10476600, Roche, Penzberg, Germany). A StepOnePlus Real-Time PCR System (Applied Biosystem, ABI, MA, USA) was used to monitor the changes of fluorescence intensity from PCR products. GAPDH was used as internal control. The data were analyzed using StepOne software version 2.0.
Cortexes from 12-month-old mice were homogenized with a pestle at the concentration of 1 μg tissue /9 μl HEPES buffer (1% CHAPS 50 mM HEPES, 10 mM EDTA, 150 mM NaCl, pH 7.4). Tissue lysates were centrifuged at 600 × g for 5 mins and supernatants were collected. 200 μl samples were pre-cleared with 50 μl protein G bead (LSKMAGG02, Millipore, Germany) rotating at room temperature for 30 mins. Pre-cleared lysates were incubated with anti-DcR3 (33302, Biolegend, CA, USA), anti-syndecan-1 (10593–1-AP, ProteinTech, IL, USA), anti-glypican-1 (sc-66910, Santa Cruz biotechnology, TX, USA), or anti-Aβ (6E10, SIG-39320, COVANCE, NJ, USA) antibodies at 4 °C overnight, and were then mixed with protein G beads rotating at room temperature for 1 h. The beads were washed with 0.1% Tween 20 in PBS for 20 mins and were eluted by SDS-sample buffer (87.5 mM Tris-HCl, 1% SDS, 30% glycerol, 0.6 M DTT, 180 μM bromphenol blue, pH 6.8) at 95 °C, 10 mins. The eluted samples and input controls were monitored by Western blot.
Gel electrophoresis and Western blotting analysis
Proteins were separated via 10% or 15% Tris-glycine SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were probed with rabbit anti-PSD95 (3450 Cell Signaling, MA, USA), mouse anti-DcR3 (33302, Biolegend, CA, USA), rabbit anti-syndecan-1 (10593–1-AP, ProteinTech, IL, USA), rabbit anti-glypican-1 (sc-66910, Santa Cruz biotechnology, TX, USA), mouse anti-Aβ (6E10, SIG-39320, COVANCE, NJ, USA), anti-YM1 (01404, Stem Cell technology, Vancouver, Canada), mouse anti-GAPDH (60004-1-Ig, ProteinTech, IL, USA), and mouse anti-actin (MAB1501, Millipore, MA, USA) antibodies. The membranes were washed and probed with the HRP-conjugated goat anti-mouse IgG and goat anti-rabbit IgG (12–349, AP132P, Millipore, MA, USA). Protein signals were developed by using a chemiluminescent substrate ECL detection system (WBKLS0500, Millipore, MA, USA) and quantified by using a luminescence imaging system (LAS-4000, Fujifilm, Japan).
Oligomeric Aβ (oAβ) fibrillar Aβ (fAβ) and DcR3 preparation
HFIP-treated Aβ1-42 peptides (rPeptide Inc. A–1163–2, GA, USA) were dissolved in 10% DMSO at 100 μM and stored at –80 °C. Before the experiment, the stock was aged at 4 °C for 24 h to generate oAβ or aged at 37 °C for 18 days to generate fAβ. A DcR3-SAS and Vector-SAS stable line were generated by transfecting the human DcR3 gene or control vector into SAS cells. Culture medium was collected after 24 h of DcR3-SAS and Vector-SAS growth for the conditioned medium experiment.
Primary neuron and microglia preparation and conditioned medium (CM) stimulation
Primary microglia were prepared from postnatal day 0–5 C57B6/J mice. The cortexes were digested with 100 U papain and 400 U DNase I in HBSS buffer at 37 °C for 30 min. Digested cells were passed through a 70-μm cell strainer (Corning NY, USA). Mixed cortical cells were grown in DMEM-F12. After 21 days incubation, microglia were isolated from a 30:37:70% Percoll (P4937, Sigma. MO, USA) gradient and were seeded in 25-T flasks for 24 h.
Primary cortical neuron cultures were prepared from postnatal day 0–1 C57B6/J mice as primary microglia but seeded at a density of 4x105 per well for 7 days in the neurobasal medium.
To obtain conditioned medium (CM) microglial culture were stimulated with the DcR3-SAS medium before, together or after incubating with Aβ for 72 h and their media were collected as pre-, co- or post-treatment Aβ/DcR3-CM. Aβ-CM was collected from microglial culture stimulated with Vector-SAS medium and Aβ for 72 h, and control-CM was collected from microglial culture stimulated with the vector-SAS medium. For the DcR3 immune-depletion control, the DcR3-SAS medium was incubated with anti-DcR3 (33302, Biolegend, CA, USA) and protein G bead (LSKMAGG02, Millipore, Germany) rotating at 4 °C overnight. DcR3 depleted SAS medium was collected for microglia treatment. For the competition assay, microglia were co-treated with DcR3 and 30 μg/ml heparin sulfate (HS) to interfere the DcR3-HSPG interaction for 8 h and then incubated with Aβ for 72 h. These conditioned media were collected and applied to primary neurons for 72 h.
Neuronal survival rate after different CM treatment was assessed using MTT (3006 Biotium Inc., CA, USA) and propidium iodide (PI) staining assays according to the manufacturer’s instructions. For the MTT assay, formazan was solubilized in lysis buffer (10% SDS and 20 mM HCl), and the concentration was determined according to the optical density at 570 nm with a Sunrise™ absorbance reader with Magellan™ data analysis software (Version 6; Tecan Switzerland).
For PI staining neurons were incubated with 10 μg/ml PI in PBS for 20 min and were fixed in 4% paraformaldehyde for immunofluorescence staining with the MAP2 antibody. The staining results were quantified as the ratio of PI+ neurons to total MAP2+ neurons by using MetaMorph® Microscopy Automation & Image Analysis Software (Molecular Devices, CA, USA).
Mouse cytokine array
The cytokines in the primary microglia conditioned medium were detected by using the mouse cytokine array C1000 (AAM-CYT-1000 RayBiotech, GA, USA). Membranes were incubated with control CM, Aβ-CM or Aβ/DcR3-CM (pre-treatment condition) for 16 h and detected with a Biotin-Streptavidin system. Signals were scanned by using a Fujinon LAS-4000 system and quantified by using Multi Gauge V3.0 software (Fujifilm Corporation, Tokyo, Japan). The level of each cytokine in the control group was set as 100.
Microglial phagocytosis assay
Purified microglia were seeded at a density of 1x105 cells/well on poly-d-lysine coated coverslips. Attached microglia were treated with oAβ or oAβ + DcR3 for 72 h. Their phagocytic ability was examined by incubating with red fluorescent carboxylated microspheres (F8821 1 μm in diameter, Polysciences Life Technologies, USA) coated with fetal calf serum at 37 °C for 30 min. After three PBS washes, microglia were fixed with 4% paraformaldehyde and stained with anti-Iba1 antibody to visualize the number of engulfed microspheres in the microglia.
Data are presented as the mean ± s.e.m. from at least three independent experiments and were analyzed using Prism software (GraphPad). Differences between data sets were analyzed by unpaired two-tailed Student's t-tests or one-way ANOVA followed by the Bonferroni post hoc test. During multiple contrast analysis, the alpha was set as 0.05 (95% confidence intervals). All the precise numbers of samples and their statistical analysis methods of each experiment are listed in Additional file 2: Table S2. A p value less than 0.05 was considered to be statistically significant.
DcR3 protects against Aβ-induced cognitive deficits and synaptic loss
To investigate the effects of DcR3 on the functional and pathological features of AD transgenic mice overexpressing mutated human APP (line J20) and human DcR3 were crossed to generate APP/DcR3 double transgenic mice. The levels of the full-length APP (FL-APP) in APP and DcR3/APP mice did not change, and nor did the level of DcR3 in DcR3 and DcR3/APP mice (Additional file 3: Figure S1). Because this line of APP mice develops memory impairments and Aβ plaques at the age of 4 months and 5 months, respectively [26, 27], we followed the behavioral changes and Aβ plaque formation in APP/DcR3, APP, DcR3, and wild-type (WT) littermates, respectively, to determine whether DcR3 modulates the pathogenesis of AD at 6 months after birth.
Contextual fear conditioning and auditory-cued fear conditioning tests were further applied to evaluate hippocampus-dependent and amygdala-dependent emotional memory respectively. During the training day, impaired learning was observed in the APP transgenic mice but not in the APP/DcR3 double transgenic mice (Fig. 1d). On day 2 of testing, the APP/DcR3 mice displayed a longer freezing time than the APP mice in the contextual fear conditioning test (Fig. 1e), suggesting that DcR3 reversed the hippocampus-dependent fear memory deficits. In contrast, there was no difference in the amygdala-dependent cued fear conditioning test among the 4 genotypes of mice (Fig. 1f). This observation suggests that DcR3 could ameliorate Aβ-induced hippocampus-related memory deficits.
We further examined the spontaneous motor activity and anxiety levels of these mice in the open field test and in the elevated plus maze. Consistent with previous findings  the APP mice traveled a longer distance in the open field and spent more time in the open arm of the elevated plus maze. In these two tests, the APP/DcR3 mice also had higher locomotor activity and lower anxiety-like behavior similar to the APP mice (Fig. 1g and h). These observations suggest that DcR3 reverses hippocampus-dependent memory impairment without changing locomotion- and anxiety-related behaviors.
DcR3 mediates neuronal protection via microglia
We further examined the protective effect of DcR3 by incubating neurons with DcR3-CM simultaneously or after exposure to Aβ respectively (Fig. 3a, DcR3 co- and post-treatment). Compared with the Aβ-CM, the survival rate was significantly increased in neurons co-treated, but not post-treated, with DcR3-CM (Fig. 3d). These results suggested that DcR3-CM-mediated protection is via preventing but not reversing Aβ-induced neurotoxic effect (Fig. 3b-d & Additional file 5: Figure S3a & S3b). To further distinguish whether the neuroprotective effect of DcR3 was contributed from microglia or neuron, primary neurons were incubated with Aβ-CM and recombinant DcR3 for 72 h (Fig. 3a, neuronal treatment). Under this condition, DcR3 failed to protect primary neuron against Aβ-induced neurotoxicity (Fig. 3e & f). These observations suggest that the DcR3-mediated neuronal protection is via modulating microglia activation, rather than promoting neuronal resistance to Aβ-CM.
To examine the quality of oAβ and fAβ structures western blot was applied to examine the aggregation states of Aβ before, after microglial treatment, and after neuronal treatment. The oligomeric (10-72 kDa) and fibrillar (in the stacking gel) structures remain the major species in oAβ and fAβ group respectively (Additional file 6: Figure S4a-c). To further confirm the importance of DcR3 in neuroprotection, DcR3 in the SAS medium were removed by the anti-DcR3 conjugated protein G beads before treating onto microglia (Additional file 6: Figure S4d). While we treated the neuron with the DcR3-depleted CM, the neuronal survival rate was not returned to normal, which indicated a critical role of DcR3 on modulating innate-related cytokine-induced cytotoxicity (Additional file 6: Figure S4e).
DcR3 reduces amyloid plaque deposition and enhances of Aβ uptake
We further asked whether DcR3 directly promotes the Aβ-induced phagocytic ability of primary microglia by in vitro culture system. To determine phagocytic ability oAβ- or oAβ + DcR3-treated primary microglia were incubated with fluorescence labeled microspheres. In the presence of DcR3, the phagocytic activities of the microglia were upregulated significantly (Fig. 5c & d). These observations suggest that DcR3 enhances the phagocytosis of microglia, which may enhance Aβ-clearance ability.
DcR3 enhances the IL-4+YM1+ M2a-like microglia population and anti-inflammatory signaling through binding with HSPGs
Although no change in microglia survival rate was found there was an obvious difference in the morphology of primary microglia at 72 h after Aβ or Aβ/DcR3 treatment in vitro. The morphology of microglia without any treatment is in fusiform and ramified shape, which are characteristics of resting microglia. After oAβ treatment for 72 h, microglia enlarged and became an amoeboid shape. In oAβ/DcR3 treated microglia, the size of amoeboid shape microglia is smaller than the oAβ group (Additional file 8: Figure S6). These observations demonstrated the potent modulatory effect of DcR3 to attenuate oAβ-induced microglia activation.
Since the sources of TNF-α and IL-1β in the brain are not only from microglia we confirmed the role of DcR3 to modulate the secretion of cytokines from microglia by using in vitro culture system. The cytokine profiles in the Aβ-CM or Aβ/DcR3-CM (from Fig. 3a, pre-treatment condition) were analyzed by cytokine array (Fig. 6d). Compared with Aβ-CM, lower levels of pro-inflammatory mediators (CD40, TNF-α, IL-1β, IL-12) with higher the levels of the M2a inducer (IL-4) and the M2a marker (YM1) were observed in Aβ/DcR3-CM (Fig. 6d and Additional file 11: Figure S9a). In contrast, the levels of M2b and M2c markers (CXCL2 and IL-10) were not altered by DcR3 (Fig. 6d). All these observations suggest that DcR3 has the potent effect to modulate cytokine secretion by modulating the activation and differentiation of microglia. It is interesting to note that DcR3 did not alter the expression of MMP9, which contributes to plaque clearance in the brain , suggesting MMP9-dependent proteolytic degradation of Aβ was not influenced by DcR3 (Additional file 11: Figure S9b). The complete list of all the changes from this cytokines array is listed in Additional file 12: Table S3. Thus, we concluded that DcR3 is able to skew microglia differentiation into IL-4+YM1+ M2a-like microglia in vivo and in vitro.
DcR3 promotes anti-inflammatory effect
The importance of microglia-neuron interaction has been implicated in many neuroinflammatory-related disorders . In the pre-plaque AD mouse oAβ and complement C1q initiate complement cascade and recruit microglia via CR3 to eliminate synapses . Manipulation of the innate immune system into alternatively M2 activated microglia has been considered as a promising therapeutic strategy for AD [11, 41]. For example, intracerebral injections of IL-4/IL-13 or IL-33 reverse memory deficits and reduce Aβ plaque load in AD mouse models [41, 42]. In addition, YM1+ cells could protect neurons during acute brain injury [43, 44]. We found that DcR3-triggered IL-4+YM1+ M2a-like microglia contribute to anti-inflammatory response and functional recovery in vitro and in vivo. DcR3 reduces Aβ − induced pro-inflammatory cytokines, TNF-α and IL-1β , to prevent severe neuroinflammation and neurodegeneration . Although DcR3 has been shown its’ ability to polarize macrophage differentiation in the periphery [24, 25], this study first presents that DcR3 modulates the complex innate immunity profiles and is able to counter Aβ-induced neuroinflammation in the brain.
In disease-related models microglia activation has dynamic, multidimensional and mosaic signatures . Generally speaking, switching activated microglia from M1 into M2 anti-inflammatory spectrum can reverse inflammatory-related diseases [12, 47]. However, microglia/ macrophage have diverse characteristics in different regions and switch dynamically in response to environmental changes [46, 48]. Studies focusing on macrophage/microglia activation in specific tissues or using particular cytokine stimulation in vitro might not reveal the complex profiles of innate immunity environment [49, 50]. In addition, the M1/M2 microglia classification has been questioned on modulating neurotrophic factors to regulate synaptic plasticity and memory [48, 51, 52]. Therefore, more evidence are needed to better understand the roles of microglia populations toward AD pathogenesis.
DcR3 promotes phagocytosis
To remove plaque via phagocytosis activated microglia are recruited to the site of plaques in AD animal models and patients [32, 53]. This recruitment is important for engulfing amyloids or tissue debris through lysosome-dependent manner or for constituting a barrier to prevents neurotoxic protofibrillar Aβ42 [32, 54, 55]. Although both astrocyte and microglia could be found near the plaques, only microglia have the ability to degrade Aβ . Inefficient phagocytosis ability of microglia has been reported in AD animal models, and down-regulating phagocytosis-related gene expression has been found in AD subjects [56, 57]. This deficit could be caused by Aβ aggregates, reactive oxygen species (ROS), and pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, and IL-18 [58, 59]. Regulating microglia phagocytosis is considered as a detrimental way to prevent tissue damage in the brain . We found that DcR3 induces more microglia activation near plaque regions (Fig. 5a-b) and enhances microglia phagocytosis to remove Aβ in vivo and in vitro (Fig. 4 & Fig. 5c-d). The enhanced phagocytic ability of Aβ + DcR3-stimulated microglia may reverse the deficit of reducing phagocytic cells in AD patients or AD mice models [61, 62]. Altogether, our results suggest a potential beneficial role of DcR3 on modulating microglia into anti-inflammatory phagocytosis status.
DcR3 interacts with HSPG to regulate neuronal survival
We found that DcR3 interacts with mouse surface HSPGs glypican-1 and syndecan-1 (Fig. 7a & b), and DcR3 neuroprotective effect can be shaded by heparin in vitro (Fig. 7d). The HSPGs on the microglia and oligodendrocytes near lesions could modulate the accumulation of senile plaques and neurofibrillary tangles. [63, 64]. Glypican-1 can bind to Aβ aggregates to upregulate ER stress and to stimulate microglia activation that results in enhanced cytotoxicity [34, 65]. Syndecans are involved in the production of Aβ , ROS , and inflammatory cytokines [35, 67]. Furthermore, deletion of HSPGs accelerates Aβ clearance in APP/PS1 mice, suggesting that inhibition of Aβ-HSPG interaction is able to suppress Aβ-induced neuroinflammation . However, the addition of heparin did not completely reverse DcR3 protection effects, which may due to the multiple roles of heparin such as promoting amyloidogenesis and modulate neuroinflammation [68, 69]. Because DcR3 interacts with HSPGs but not Aβ in our AD mouse model (Fig. 7a-c), DcR3-mediated neuronal protection may compete Aβ binding to HSPG or suppress HSPGs-CD14/TLR4 mediated inflammation . The functions of HSPGs binding domain in DcR3 and its contributions to innate systems requires further analysis.
The anti-inflammatory treatments using cytokines and DcR3
Several clinical studies have shown contradictory evidence for non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment or prevention of AD . These NSAIDs cannot be used in high doses or for a long period of time because of potential side effects in the cardiovascular or gastrointestinal systems . In all NSAID clinical trials, cognitive performance had no significant improvements, and inconsistent results were reported for indomethacin [72, 73], ibuprofen [74, 75], celecoxib , rofecoxib [77, 78], and naproxen treatments . A potential reason for the failure of anti-inflammatory approaches is that different anti-inflammatory cytokines induce diverse responses. For example, one anti-inflammatory cytokine, IL-10, facilitates Aβ aggregation, inhibits microglial phagocytic ability, and causes cognitive dysfunction in APP mice [79, 80]. In contrast, the other anti-inflammatory cytokine, IL-4, triggers microglia phagocytosis to reduce Aβ deposition [15, 81]. Thus, the IL-10 induced microglia may be harmful but IL-4+ microglia may be beneficial to AD-related symptoms. For novel treatment approaches, it is important to identify the microglia subtypes that ameliorates AD pathogenesis.
In comparison to other anti-inflammatory treatments DcR3 is a non-cytokine that induces an anti-inflammatory response, neutralizes FasL-induced cell death, and reduces ROS production . Therefore, DcR3 may be an alternative agent for designing the future treatment. DcR3 concentration in our transgenic mouse serum is 268.6 ± 59.2 pg/ml (Additional file 3: Figure S1), which is slightly higher than healthy human (63.7 ± 21.9 pg/ml) but similar to the asthma patients (266.1 ± 60.6 pg/mL) . Because DcR3 is highly expressed in the endometrium during pregnancy, it appears to be a safe natural immunomodulator to suppress neuronal inflammation in the presence of dangerous endogenous signals . These findings suggested that DcR3 may be a safe therapeutic agent for early AD and other neuroinflammation-related diseases.
In summary, our findings are in line with the current idea that switching microglia phenotype modulates amyloid pathogenesis. Especially, we first identified that DcR3 induces phagocytosis ability and creates an IL-4+YM1+ environment to clear Aβ plaque in the brain. DcR3 might also regulate surface HSPGs activity that mediates Aβ-related neurodegeneration and pro-inflammatory signalings (Fig. 8). Taken together, the DcR3-induced specific IL-4+YM1+ innate response could broaden our views on AD early-intervention and bring a novel thinking on medical development.
Analysis of variance
Amyloid precursor protein
Decoy receptor 3
Enzyme-linked immunosorbent assays
Full-length amyloid precursor protein
Heparan sulfate WT, Wild-type
Non-steroidal anti-inflammatory drugs
Polyacrylamide gel electrophoresis
Quantitative real-time Polymerase Chain Reaction
Reactive oxygen species
Tumor necrosis factor receptor
Tumor necrosis factor alpha
We thank Drs. Ding-I Yang, Young-Ji Shiao, Nien-Jung Chen, Li-Chung Hsu, and Cheng-Chang Lien for the comments on this work. We also thank Po-Han Wei, Chih-Wei Sung, Ming-Ting Huang, Chien-Chun Chen, Yen-Ching Huang, and Yen-Chen Lin for experimental assistance. Behavioral studies were carried out at the Animal Behavioral Core at Brain Research Center, National Yang-Ming University. The technical services of confocal images were provided by Imaging Core Facility of Nanotechnology of the UST-NYMU. We are also grateful to the Transgenic Mouse Model Core Facility of the National Core Facility Program for Biotechnology, National Science Council and the Gene Knockout Mouse Core Laboratory of National Taiwan University Center of Genomic Medicine for technical services.
This work was supported by Taiwan Ministry of Science and Technology grant (MOST-104–2320–B–010–027 for IHC and MOST 105–2321–B–001–053, MOST 105–2811–B–001–0998 for SLH), Summit and Thematic Research Project (MOST–104–210–01–09–02, MOST–105–0210–01–13–01) of Academia Sinica, National Health Research Institutes (NHRI-EX103-10338NI, NHRI-EX106-10614NI), Cheng Hsin General Hospital (105F003C27), Yen Tjing Ling Medical Foundation (CI-106-2), Taipei Veterans General Hospital grant (V103E4-002), and Taiwan Ministry of Education Aim for Top University Grant.
Availability of data and materials
The dataset supporting the conclusions of this article is included within the article and its Additional files 1, Additional files 2, Additional files 3, Additional files 4, Additional files 5, Additional files 6, Additional files 7, Additional files 8, Additional files 9, Additional files 10, Additional files 11, Additional files 12 and Additional files 13 (Additional file: Figure S1-10, Table S1-3).
YLL, SLH and IHC wrote the manuscript. YLL, SLH and IHC participated in experimental design, execution and data interpretation. YLL was responsible for conducting all the studies; WTC undertook co-immunoprecipitation; YYL assisted in DcR3 depletion assay and PSD95 immunoblotting; PHL assisted in primary culture and took confocal images. IHC and SLH conceived the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
All animal procedures and their care were carried out in accordance the National Institute of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of National Yang-Ming University.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.View ArticlePubMedGoogle Scholar
- Ashe KH, Zahs KR. Probing the biology of Alzheimer’s disease in mice. Neuron. 2010;66:631–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A, Vissel B. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One. 2013;8:e59586.View ArticlePubMedPubMed CentralGoogle Scholar
- ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer’s disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement. 2015;11:216–25. e211.View ArticleGoogle Scholar
- Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3:136.PubMedPubMed CentralGoogle Scholar
- Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004;24:9838–46.View ArticlePubMedGoogle Scholar
- Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29:13435–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Jang E, Lee S, Kim JH, Seo JW, Lee WH, Mori K, Nakao K, Suk K. Secreted protein lipocalin-2 promotes microglial M1 polarization. FASEB J. 2013;27:1176–90.View ArticlePubMedGoogle Scholar
- David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci. 2011;12:388–99.View ArticlePubMedGoogle Scholar
- Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012;43:3063–70.View ArticlePubMedGoogle Scholar
- Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–8.View ArticlePubMedGoogle Scholar
- Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53:1181–94.View ArticlePubMedGoogle Scholar
- Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.View ArticlePubMedPubMed CentralGoogle Scholar
- Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012;13:151–8.PubMedGoogle Scholar
- Pepe G, Calderazzi G, De Maglie M, Villa AM, Vegeto E. Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflammation. 2014;11:211.View ArticlePubMedPubMed CentralGoogle Scholar
- Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, Degos V, Jacotot E, Hagberg H, Savman K, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16:1896–905.View ArticlePubMedPubMed CentralGoogle Scholar
- Cherry JD, Olschowka JA, O’Banion MK. Arginase 1+ microglia reduce Abeta plaque deposition during IL-1beta-dependent neuroinflammation. J Neuroinflammation. 2015;12:203.View ArticlePubMedPubMed CentralGoogle Scholar
- Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol. 2002;168:4846–53.View ArticlePubMedGoogle Scholar
- Zhang J, Salcedo TW, Wan X, Ullrich S, Hu B, Gregorio T, Feng P, Qi S, Chen H, Cho YH, et al. Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest. 2001;107:1459–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res. 2004;64:1122–9.View ArticlePubMedGoogle Scholar
- Chang YC, Chan YH, Jackson DG, Hsieh SL. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J Immunol. 2006;176:173–80.View ArticlePubMedGoogle Scholar
- Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011;81:838–47.View ArticlePubMedGoogle Scholar
- Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 2008;111:5054–63.View ArticlePubMedGoogle Scholar
- Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC, Hsieh SL. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol. 2012;188:2464–71.View ArticlePubMedGoogle Scholar
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050–8.PubMedGoogle Scholar
- Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivali J, Lesne S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818–28.View ArticlePubMedGoogle Scholar
- Sinclair LI, Tayler HM, Love S. Synaptic protein levels altered in vascular dementia. Neuropathol Appl Neurobiol. 2015;41:533–43.View ArticlePubMedPubMed CentralGoogle Scholar
- Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer’s disease. Acta Neuropathol. 2011;122:285–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramirez-Amaya V, Balderas I, Sandoval J, Escobar ML, Bermudez-Rattoni F. Spatial long-term memory is related to mossy fiber synaptogenesis. J Neurosci. 2001;21:7340–8.PubMedGoogle Scholar
- Gilbert PE, Brushfield AM. The role of the CA3 hippocampal subregion in spatial memory: a process oriented behavioral assessment. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:774–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281:24566–74.View ArticlePubMedGoogle Scholar
- Watanabe N, Araki W, Chui DH, Makifuchi T, Ihara Y, Tabira T. Glypican-1 as an Abeta binding HSPG in the human brain: its localization in DIG domains and possible roles in the pathogenesis of Alzheimer’s disease. FASEB J. 2004;18:1013–5.PubMedGoogle Scholar
- Kaur C, Sivakumar V, Yip GW, Ling EA. Expression of syndecan-2 in the amoeboid microglial cells and its involvement in inflammation in the hypoxic developing brain. Glia. 2009;57:336–49.View ArticlePubMedGoogle Scholar
- Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699–703.View ArticlePubMedGoogle Scholar
- Sandwall E, O’Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP. Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology. 2010;20:533–41.View ArticlePubMedGoogle Scholar
- O’Callaghan P, Li JP, Lannfelt L, Lindahl U, Zhang X. Microglial heparan sulfate proteoglycans facilitate the cluster-of-differentiation 14 (CD14)/toll-like receptor 4 (TLR4)-dependent inflammatory response. J Biol Chem. 2015;290:14904–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F, Vyssotski AL, Bifone A, Gozzi A, Ragozzino D, Gross CT. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17:400–6.View ArticlePubMedGoogle Scholar
- Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron. 2006;49:489–502.View ArticlePubMedGoogle Scholar
- Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, Cheung TH, Zhang B, Fu WY, Liew FY, Ip NY. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016;113:2705-2713.Google Scholar
- Perego C, Fumagalli S, De Simoni MG. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation. 2011;8:174.View ArticlePubMedPubMed CentralGoogle Scholar
- Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, Prockop DJ. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A. 2008;105:14638–43.View ArticlePubMedPubMed CentralGoogle Scholar
- Ye L, Huang Y, Zhao L, Li Y, Sun L, Zhou Y, Qian G, Zheng JC. IL-1beta and TNF-alpha induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J Neurochem. 2013;125:897–908.View ArticlePubMedPubMed CentralGoogle Scholar
- Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong W, Embury CM, Lu Y, Whitmire SM, Dyavarshetty B, Gelbard HA, Gendelman HE, Kiyota T. The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-beta degradation. J Neuroinflammation. 2016;13:184.View ArticlePubMedPubMed CentralGoogle Scholar
- Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19:987–91.View ArticlePubMedGoogle Scholar
- Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, Tsuneyama K, Nagai Y, Takatsu K, Urakaze M, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes. 2009;58:2574–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, Guerau-de-Arellano M. Novel markers to delineate murine M1 and M2 macrophages. PLoS One. 2015;10:e0145342.View ArticlePubMedPubMed CentralGoogle Scholar
- Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691–705.View ArticlePubMedPubMed CentralGoogle Scholar
- Parkhurst CN, Yang G, Ninan I, Savas JN, Yates 3rd JR, Lafaille JJ, Hempstead BL, Littman DR, Gan WB. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596–609.View ArticlePubMedPubMed CentralGoogle Scholar
- Wisniewski HM, Wegiel J, Wang KC, Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer’s disease. Acta Neuropathol. 1992;84:117–27.View ArticlePubMedGoogle Scholar
- Ma Y, Bao J, Zhao X, Shen H, Lv J, Ma S, Zhang X, Li Z, Wang S, Wang Q, Ji J. Activated cyclin-dependent kinase 5 promotes microglial phagocytosis of fibrillar beta-amyloid by up-regulating lipoprotein lipase expression. Mol Cell Proteomics. 2013;12:2833–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176.View ArticlePubMedPubMed CentralGoogle Scholar
- Marsh SE, Abud EM, Lakatos A, Karimzadeh A, Yeung ST, Davtyan H, Fote GM, Lau L, Weinger JG, Lane TE, et al. The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A. 2016;113:E1316–1325.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell. 2013;153:707–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Ritzel RM, Patel AR, Pan S, Crapser J, Hammond M, Jellison E, McCullough LD. Age- and location-related changes in microglial function. Neurobiol Aging. 2015;36:2153–63.View ArticlePubMedGoogle Scholar
- Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, Chen XC. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer’s disease. Mol Neurodegener. 2011;6:45.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160:1061–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhattacharjee S, Zhao Y, Lukiw WJ. Deficits in the miRNA-34a-regulated endogenous TREM2 phagocytosis sensor-receptor in Alzheimer’s disease (AD); an update. Front Aging Neurosci. 2014;6:116.PubMedPubMed CentralGoogle Scholar
- Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G, Jain M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2013;34:1060–8.View ArticlePubMedGoogle Scholar
- van Horssen J, Otte-Holler I, David G, Maat-Schieman ML, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer’s disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. 2001;102:604–14.View ArticlePubMedGoogle Scholar
- Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer’s disease. Sci Transl Med. 2016;8:332ra344.Google Scholar
- O’Callaghan P, Sandwall E, Li JP, Yu H, Ravid R, Guan ZZ, van Kuppevelt TH, Nilsson LN, Ingelsson M, Hyman BT, et al. Heparan sulfate accumulation with Abeta deposits in Alzheimer’s disease and Tg2576 mice is contributed by glial cells. Brain Pathol. 2008;18:548–61.PubMedPubMed CentralGoogle Scholar
- Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. J Biol Chem. 2003;278:48651–7.View ArticlePubMedGoogle Scholar
- Zhang X, Wu C, Song J, Gotte M, Sorokin L. Syndecan-1, a cell surface proteoglycan, negatively regulates initial leukocyte recruitment to the brain across the choroid plexus in murine experimental autoimmune encephalomyelitis. J Immunol. 2013;191:4551–61.View ArticlePubMedGoogle Scholar
- Zhang X, Li JP. Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci. 2010;93:309–34.View ArticlePubMedGoogle Scholar
- Simard JM, Tosun C, Ivanova S, Kurland DB, Hong C, Radecki L, Gisriel C, Mehta R, Schreibman D, Gerzanich V. Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage. Transl Stroke Res. 2012;3:155–65.View ArticlePubMedPubMed CentralGoogle Scholar
- Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci. 2010;2:19.Google Scholar
- Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104–13.View ArticlePubMedPubMed CentralGoogle Scholar
- Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43:1609–11.View ArticlePubMedGoogle Scholar
- de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, Kremer B. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One. 2008;3:e1475.View ArticlePubMedPubMed CentralGoogle Scholar
- Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer’s models. Neuropsychopharmacology. 2005;30:1111–20.View ArticlePubMedGoogle Scholar
- Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res. 2009;21:102–10.View ArticlePubMedGoogle Scholar
- Group AR, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896–905.View ArticleGoogle Scholar
- Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC, Rofecoxib Protocol 091 Study G. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62:66–71.View ArticlePubMedGoogle Scholar
- Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204–15.View ArticlePubMedGoogle Scholar
- Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85:519–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Guillot-Sestier MV, Doty KR, Gate D, Rodriguez Jr J, Leung BP, Rezai-Zadeh K, Town T. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron. 2015;85:534–48.View ArticlePubMedPubMed CentralGoogle Scholar
- Latta CH, Sudduth TL, Weekman EM, Brothers HM, Abner EL, Popa GJ, Mendenhall MD, Gonzalez-Oregon F, Braun K, Wilcock DM. Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-beta using BV2 microglial cells and APP/PS1 transgenic mice. J Neuroinflammation. 2015;12:41.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Shen D, Wang VM, Yu CR, Wang RX, Tuo J, Chan CC. Enhanced apoptosis in retinal pigment epithelium under inflammatory stimuli and oxidative stress. Apoptosis. 2012;17:1144–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen MH, Kan HT, Liu CY, Yu WK, Lee SS, Wang JH, Hsieh SL. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. J Formos Med Assoc. 2016;116:49–56.Google Scholar
- Chen HF, Chen JS, Shun CT, Tsai YF, Ho HN. Decoy receptor 3 expression during the menstrual cycle and pregnancy, and regulation by sex steroids in endometrial cells in vitro. Hum Reprod. 2009;24:1350–8.View ArticlePubMedGoogle Scholar